StockNews.AI
ESLA
StockNews.AI
181 days

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital

1. D. Boral Capital initiates coverage on Estrella with a Buy rating. 2. A 12-month price target of $16.00 suggests potential upside.

2m saved
Insight
Article

FAQ

Why Bullish?

A Buy rating from a reputable investment bank typically drives investor confidence, similar to prior ratings affecting stocks positively.

How important is it?

Analyst ratings can significantly influence investor behavior, impacting stock prices in the near term.

Why Short Term?

The immediate effect of an analyst upgrade often influences stock price quickly, as seen when other companies received buy recommendations.

Related Companies

ESLAESLAW
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that D. Boral Capital LLC (“D. Boral Capital”), a leading investment bank, has initiated coverage on the Company, assigning a Buy rating to Estrella and established a 12-month price target of $16.00. Valuation Highlights.

Related News